Jason Lettmann
CIK: 0001688269
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ALX ONCOLOGY HOLDINGS INC
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Aug 17, 2026ALXO
ALX ONCOLOGY HOLDINGS INC
Sale(S)Direct2.2K shares at avg. $1.93$4K - Mar 19, 2026ALXO
ALX ONCOLOGY HOLDINGS INC
Sale(S)Direct12.3K shares at avg. $2.17$27K - Feb 17, 2026ALXO
ALX ONCOLOGY HOLDINGS INC
Tax Payment(F)Direct2.2K shares at avg. $2.27$5K - Jan 26, 2026ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectStock option (right to buy)
912K shares- - Oct 14, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectEmployee Stock Option (right to buy)
597.5K shares- - Sep 17, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Purchase(P)Direct71.2K shares at avg. $1.08$77K - Sep 16, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Purchase(P)Direct21.1K shares at avg. $1.07$22K - Aug 15, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Sale(S)Direct2.4K shares at avg. $0.64$2K - Apr 11, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectEmployee Stock Option (right to buy)
125K shares- - Mar 14, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)Direct42K shares- - Feb 19, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Sale(S)Direct2.2K shares at avg. $1.15$2K - Jan 21, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectEmployee Stock Option (right to buy)
478K shares- - Dec 2, 2024ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectEmployee Stock Option (right to buy)
200K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 17, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | Sale(S) | 2,230 | $1.93 | $4,304 | Direct |
| Mar 19, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | Sale(S) | 12,311 | $2.17 | $26,715 | Direct |
| Feb 17, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | Tax Payment(F) | 2,201 | $2.27 | $4,996 | Direct |
| Jan 26, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Stock option (right to buy) | 912,000 | - | - | Direct |
| Oct 14, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Employee Stock Option (right to buy) | 597,500 | - | - | Direct |
| Sep 17, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Purchase(P) | 71,163 | $1.08 | $76,892 | Direct |
| Sep 16, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Purchase(P) | 21,070 | $1.07 | $22,461 | Direct |
| Aug 15, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Sale(S) | 2,382 | $0.64 | $1,525 | Direct |
| Apr 11, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Employee Stock Option (right to buy) | 125,000 | - | - | Direct |
| Mar 14, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) | 42,000 | - | - | Direct |
| Feb 19, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Sale(S) | 2,159 | $1.15 | $2,483 | Direct |
| Jan 21, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Employee Stock Option (right to buy) | 478,000 | - | - | Direct |
| Dec 2, 2024 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Employee Stock Option (right to buy) | 200,000 | - | - | Direct |
1-13 of 13 transactions
About Lettmann Jason
Lettmann Jason (SEC CIK 0001688269) files insider reports with the SEC as CHIEF EXECUTIVE OFFICER of ALX ONCOLOGY HOLDINGS INC (ALXO).
Signal8 holds 12 ownership filings by Lettmann Jason, all Form 4s, filed between Dec 4, 2024 and Aug 18, 2026. Those filings report 13 transactions, from Dec 2, 2024 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lettmann Jason's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Lettmann Jason
- Aug 17, 2026: Open-market sale of ALXO shares (Form 4, code S).
- Mar 19, 2026: Open-market sale of ALXO shares (Form 4, code S).
- Feb 17, 2026: Tax withholding of ALXO shares (Form 4, code F).
- Jan 26, 2026: Grant or award of ALXO derivative securities (Form 4, code A).
- Oct 14, 2025: Grant or award of ALXO derivative securities (Form 4, code A).
Other insiders filing for ALX ONCOLOGY HOLDINGS INC (ALXO)
- Wong Shelly, SVP, FINANCE AND CAO
- Knight Jeff E., Chief Dev & Operating Officer
- Klencke Barbara, Chief Medical Officer
- GOODMAN COREY S, Director
- Shantharam Harish, Chief Financial Officer
- Garland J. Scott, Director